The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Glenmark is the first company in India to market the innovative FDC of Indacaterol
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Subscribe To Our Newsletter & Stay Updated
